Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Communicable

Communicable artwork

Communicable E17: Season’s greetings from the editors & holiday replay of late-breaker clinical trials at ESCMID Global 2024

Dec 29, 20241 hr 5 minAudio
ShareXLinkedInFacebookWhatsAppEmail

The last episode of the year carries a special end-of-year message from the CMI Comms editors and replays the very first episode of Communicable aired on 10 May 2024, in which editors Angela Huttner, Marc Bonten, and Erin McCreary discuss late-breaker clinical trials presented at ESCMID Global 2024 in Barcelona, providing insights into the trials’ designs, results, and implications. The DOTS trial compared two doses of long-acting dalbavancin to standard of care in patients with complicated S. aureus bacteraemia. GAME-CHANGER compared cefiderocol to standard of care for Gram-negative infections. PediCAP compared oral step-down therapy with amoxicillin with or without clavulanic acid at shorter durations to the current WHO-recommended standard of five days of intravenous antibiotic therapy in children with severe pneumonia. Additional results from the MULTICAP and CLEEN trials, the CAMERA-2 follow-on in vitro analysis, and the Burkina Faso Escherichia coli transmission study are also discussed. This episode was peer-reviewed by Dr. Yousra Kherabi (Clinical Trials Research Section, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA; Infectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris; and Université Paris Cité, Inserm, IAME, Paris, France).

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Communicable E67: New antifungals & how to use them

    Nov 15, 202650 minAudio

    In this episode of Communicable, hosts Annie Joseph and Josh Nosanchuk welcome Neil Stone and Jeniel Nett to discuss new and emerging antifungal treatments, including ibrexafungerp, rezafungin and olorofim, among...

    Credit the people on this episode

  2. Communicable E66: Diagnostics in the AMR era

    Nov 1, 202651 minAudio

    Ahead of World Antimicrobial Resistance Awareness Week (WAAW), Communicable presents a special episode exploring the role of diagnostics within the space of antimicrobial resistance (AMR). Hosts Thomas Tängdén and Annie...

    Credit the people on this episode

  3. Communicable E65: Quarterly catch-up (October 2026 edition)

    Oct 18, 202649 minAudio

    In this episode of Communicable, Emily McDonald returns for another ‘Quarterly catch-up’ and is joined by Angela Huttner as co-host. Together, they review four recent randomised clinical trials, focusing on antibiotic...

    Credit the people on this episode

  4. Communicable E64: Getting micro on macrolides for community-acquired pneumonia

    Oct 4, 202650 minAudio

    In this episode of Communicable, hosts Emily McDonald and Marc Bonten are joined by Sylvain Lother and Valentijn Schweitzer for a discussion on the use of macrolides in community-acquired pneumonia. Together, they...

    Credit the people on this episode

  5. Communicable E63: Does oseltamivir harm critically ill patients? The REMAP-CAP results

    Sep 20, 20261 hr 3 minAudio

    At the Critical Care Reviews meeting in Belfast in June this year, REMAP-CAP investigators presented results suggesting that oseltamivir may be harmful in critically ill patients with influenza, upending a long-standing...

    Credit the people on this episode